Introduction {#Sec1}
============

Anastomotic leakage (AL) is one of the most devastating complications following colorectal resection for left-sided colorectal cancer (CRC) \[[@CR1]\]. It leads to increased morbidity, mortality, treatment costs, and prolonged hospitalization. The AL rate varies between 6 and 12% after rectal resection and between 2 and 4% after sigmoid resection \[[@CR2]\]. Male sex, elderly age, obesity, severe comorbidities (higher American Society of Anesthesiology (ASA) score), prolonged surgery time, perioperative blood transfusions, low anastomosis, and neoadjuvant chemoradiotherapy are proposed risk factors for AL \[[@CR3], [@CR4]\]. AL may occur in patients without any risk factors as well, and therefore, it remains a challenging issue in CRC surgery.

While AL has a negative impact on short-term surgical outcomes, the impact on long-term outcomes remains controversial. The study led by Karim et al. concluded that AL impairs overall survival (OS) and disease-free survival (DFS) \[[@CR5]\]. In contrast, Crippa et al. reported similar outcomes in patients with or without AL in terms of OS, DFS, and local recurrence rates \[[@CR6]\]. Therefore, the present study aimed to determine the impact of AL on the long-term outcomes in patients undergoing surgery for left-sided CRC and to identify the risk factors for AL after sigmoid and rectal resection.

Materials and methods {#Sec2}
=====================

Ethics {#Sec3}
------

Vilnius regional research ethics committee approval (no. 2019/3-116-608) was obtained before the study. The study was conducted according to the Declaration of Helsinki.

Patients {#Sec4}
--------

All patients who underwent left-sided colorectal resection with a primary anastomosis below 15 cm from anal verge between January 2014 and December 2018 at two major gastrointestinal cancer treatment centers in Lithuania---Vilnius University Hospital Santaros Klinikos and National Cancer Institute---were screened for eligibility. Patients who underwent emergency surgery or those with a benign pathology were excluded. Finally, all patients who underwent elective colorectal resection with primary anastomosis for left-sided CRC were included in the study (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flowchart of the patients selection process

Data collection {#Sec5}
---------------

All participants' characteristics were obtained from the prospectively collected and maintained databases. They included age, gender, body mass index (BMI), American Society of Anesthesiologists (ASA) score, comorbidities, Charlson comorbidity index (CCI), history of neoadjuvant treatment, tumor localization, surgical approach (open surgery and minimally invasive surgery, laparoscopic surgery, hand-assisted laparoscopic surgery, natural orifice specimen extraction surgery, and transanal total mesorectal excision surgery (taTME)), the level of the anastomosis, diverting ileostomy, simultaneous operation, high or low ligation of the inferior mesenteric artery (IMA), results of the intraoperative air-leak test, postoperative complications including AL, and the data of follow-up including progression of the disease. Tumor stage was coded according to the TNM system as described in the Union Internationale Contre le Cancer/American Joint Committee on Cancer 8th edition.

Study outcomes {#Sec6}
--------------

The primary outcome of the study was overall survival (OS) in patients with or without AL. The secondary outcomes included disease-free survival (DFS), 30-day mortality, and the risk factors for AL.

OS was defined as the time from surgery to death. Data on survival and date of death were collected from the National Lithuanian Cancer registry and the National Lithuanian death registry. Mortality registration rates, from both resources, were over 98%. DFS was defined as the time from surgery to disease progression including local or distant recurrence.

AL definition {#Sec7}
-------------

AL was defined as a defect at the anastomotic area with a communication between the intra- and extra-luminal compartments. AL was confirmed by digital rectal examination, endoscopic evaluation, or radiologic tests with proven extravasation of rectal contrast or evidence of a peri-anastomotic fluid collection with pus or feculent aspirate \[[@CR7]\].

Statistical analysis {#Sec8}
--------------------

All statistical analysis was performed by statistical package SPSS 25.0 (SPSS, Chicago, IL, USA). Patients were grouped to those who developed AL (AL) and those who did not develop AL (non-AL). All data were checked for normality. Continuous variables were compared by a two-tailed *t* test, one-way ANOVA, or non-parametric tests where appropriate and expressed as means ± standard deviation or median with first (Q1) and third (Q3) quartiles. Categorical data were expressed as proportions with percentages and compared by the chi-square test and Fisher exact test. To identify independent variables associated with anastomotic leakage, all potential risk factors were included in subsequent multivariable logistic regression analyses. Kaplan-Meier method was used for OS analysis, and survival curves were compared by the log-rank test. Multivariable survival analysis was performed using the Cox proportional hazards model (hazard ratio and 95% confidence intervals). A *p* value of \< 0.05 was considered to be significant in all statistical analyses.

Results {#Sec9}
=======

Study participants {#Sec10}
------------------

A total of 900 patients with a mean age of 65 ± 10 years were included in the study. For further analysis, patients were divided into sigmoid and rectal surgery sub-groups based on a tumor location. The AL rate after sigmoid and rectal surgery was 5.1% (13 of 257) and 10.7% (69 of 643), respectively. Baseline data of the patients are included in Table [1](#Tab1){ref-type="table"}. Table 1Basic characteristics of the sigmoid and rectal surgery groupsSigmoid surgery (*n* = 257)Rectal surgery (*n* = 643)*p* valueAge65.4 ± 10.265.1 ± 10.90.172BMI\< 30152 (63.1%)472 (77.6%)0.001≥ 3089 (36.9%)136 (22.4%)GenderFemale117 (45.5%)300 (46.7%)0.768Male140 (54.5%)343 (53.3%)ASAI--II160 (65.3%)430 (70.1%)0.167III--IV85 (34.7%)183 (29.9%)CCI≤ 5180 (70.0%)470 (73.1%)0.365\> 577 (30.0%)173 (26.9%)T stageT0--T286 (33.5%)215 (33.4%)0.999T3--T4171 (66.5%)428 (66.6%)N stage0149 (59.4%)392 (61.6%)0.822172 (28.7%)172 (27.0%)230 (12.0%)72 (11.3%)M stage0218 (84.8%)592 (92.1%)0.002139 (15.2%)51 (7.9%)TNM stage05 (1.9%)7 (1.1%)0.006166 (25.7%)160 (24.9%)271 (27.6%)198 (30.8%)375 (29.2%)227 (35.3%)440 (15.6%)52 (7.9%)Approach of surgeryOpen78 (30.4%)364 (56.6%)0.001MI179 (69.6%)279 (43.4%)Postoperative complicationsNo208 (80.9%)413 (64.2%)0.001Yes49 (19.1%)230 (35.8%)ALNo244 (94.9%)574 (89.3%)0.007Yes13 (5.1%)69 (10.7%)*ASA* American Society of Anesthesiologists classification score, *CCI* Charlson comorbidity index score, *MI* minimally invasive, *AL* anastomotic leakage

Risk factors for AL {#Sec11}
-------------------

Table [2](#Tab2){ref-type="table"} shows the univariate analysis of all potential risk factors for AL after sigmoid and rectal surgery. Higher ASA score (III--IV, *p* = 0.002) was associated with AL in patients undergoing sigmoid surgery, while male sex (*p* = 0.002), higher CCI score (\> 5, *p* = 0.004), and advanced tumor stage (T3/T4, *p* = 0.031) was associated with AL in patients with rectal cancer. Table 2Univariate analysis of risk factors for postoperative AL in sigmoid and rectal surgerySigmoid surgeryRectal surgeryNon-ALAL*p* valueNon-ALAL*p* value(*n* = 244)(*n* = 13)(*n* = 574)(*n* = 69)BMI\< 30147 (96.7%)5 (3.3%)0.337424 (89.8%)48 (10.2%)0.999≥ 3083 (93.3%)6 (6.7%)122 (89.7%)14 (10.3%)GenderFemale111 (94.9%)6 (5.1%)0.999280 (93.3%)20 (6.7%)0.002Male133 (95.0%)7 (5.0%)294 (85.7%)49 (14.3%)ASAI--II158 (98.8%)2 (1.3%)0.002389 (90.5%)41 (9.5%)0.154III--IV76 (89.4%)9 (10.6%)158 (86.3%)25 (13.7%)CCI≤ 5172 (95.6%)8 (4.4%)0.538430 (91.5%)40 (8.5%)0.004\> 572 (93.5%)5 (6.5%)144 (83.2%)29 (16.8%)Ischemic heart diseaseYes13 (100%)0 (0%)0.99926 (86.7%)4 (13.3%)0.551No231 (94.7%)13 (5.3%)548 (89.4%)65 (10.6%)Diabetes mellitusYes28 (90.3%)3 (9.7%)0.19754 (84.4%)10 (15.6%)0.200No216 (95.6%)10 (4.4%)520 (89.8%)59 (10.2%)History of CVDYes8 (100%)0 (0.0%)0.99917 (89.5%)2 (10.5%)0.999No236 (94.8%)13 (5.2%)557 (89.3%)67 (10.7%)Chronic renal failureYes4 (100%)0 (0.0%)0.9998 (88.9%)1 (11.1%)0.999No240 (94.9%)13 (5.1%)566 (89.3%)68 (10.7%)Neoadjuvant treatmentYes8 (88.9%)1 (11.1%)0.378161 (88.0%)22 (12.0%)0.484No236 (95.2%)12 (4.8%)413 (89.8%)47 (10.2%)Approach of surgeryOpen71 (91.0%)7 (9.0%)0.069320 (87.9%)44 (12.1%)0.247MI173 (96.6%)6 (3.4%)254 (91.0%)25 (9.0%)Anastomosis level from anal verge≤ 520 (95.2%)1 (4.8%)0.999155 (89.1%)19 (10.9%)0.1376--12235 (86.4%)37 (13.6%)\> 12178 (93.7%)12 (6.3%)81 (94.2%)5 (5.8%)IleostomyYes0 (0.0%)1 (100%)0.051330 (88.5%)43 (11.5%)0.519No244 (95.3%)12 (4.7%)244 (90.4%)26 (9.6%)T stageT0--T284 (97.7%)2 (2.3%)0.230200 (93.0%)15 (7%)0.031T3--T4160 (93.6%)11 (6.4%)374 (87.4%)54 (12.6%)N stage0143 (96%)6 (4.0%)0.253357 (91.1%)35 (8.9%)0.130170 (97.2%)2 (2.8%)149 (86.6%)23 (13.4%)227 (90.0%)3 (10%)61 (84.7%)11 (15.3%)M stage0209 (95.9%)9 (4.1%)0.117531 (89.7 %)61 (10.3 %)0.238135 (89.7%)4 (10.3%)43 (84.3 %)8 (15.7 %)TNM stage05 (100%)0 (0.0%)0.2216 (85.7%)1 (14.3%)0.568164 (97.0%)2 (3.0%)147 (91.9%)13 (8.1%)268 (95.8%)3 (4.2%)178 (89.9%)20 (10.1%)372 (96.0%)3 (4%)200 (88.1%)27 (11.9%)435 (87.5%)5 (12.5%)43 (84.3%)8 (15.7%)Ligation of IMAHigh189 (95.9%)8 (4.1%)0.165442 (88.4%)58 (11.6%)0.265Low50 (90.9%)5 (9.1%)117 (92.1%)10 (7.9%)Simultaneous operationYes20 (90.9%)2 (9.1%)0.30853 (85.5%)9 (14.5%)0.286No224 (95.3%)11 (4.7%)521 (89.7%)60 (10.3%)Air-water testYes121 (96.8%)4 (3.2%)0.255454 (88.7%)58 (11.3%)0.429No119 (93.0%)9 (7.0%)116 (91.3%)11 (8.7%)*BMI* body mass index, *ASA* American Society of Anesthesiologists classification score, *CCI* Charlson comorbidity index score, *CVD* cardiovascular disease, *MI* minimally invasive, *IMA* inferior mesenteric artery, *AL* anastomotic leakage

Further, the multivariable analysis confirmed a higher ASA score (III--IV; OR = 10.539; *p* = 0.007) as an independent risk factor for AL after sigmoid surgery (Table [3](#Tab3){ref-type="table"}). The same analysis confirmed male sex (OR = 2.403, *p* = 0.004), higher CCI score (\> 5, OR = 1.720, *p* = 0.025), and advanced tumor stage (T3/4, OR = 2.250; *p* = 0.017) were among risk factors for AL after rectal surgery (Table [4](#Tab4){ref-type="table"}). Table 3Multivariable analysis of risk factors for postoperative AL in sigmoid surgeryRisk factorOdds ratio95% CI*p* valueAge0.9620.878--1.0540.632GenderMale0.8340.179--3.8820.784BMI\> 301.5190.283--8.1530.119ASAIII--IV10.5391.292--85.9760.007CCI\> 50.3480.029--4.1990.928Diabetes mellitusYes2.1500.285--16.2330.095Surgery typePalliative1.7260.052--57.2730.601Neoadjuvant treatmentYes9.6570.269--346.4010.307Anastomosis typeStapled0.9010.092--8.8210.316Ligation of IMAHigh0.6700.093--4.8480.081Air-water testNo1.0840.060--19.5930.187Simultaneous operationYes1.3180.088--19.7480.904T stageT3--T40.8870.122--6.4700.408Approach of surgeryOpen0.4380.070--2.7310.079*BMI* body mass index, *ASA* American Society of Anesthesiologists classification score, *CCI* Charlson comorbidity index score, *IMA* inferior mesenteric artery, *AL* anastomotic leakageTable 4Multivariable analysis of risk factors for postoperative AL in rectal surgeryRisk factorOdds ratio95% CI*p* valueGenderMale2.4031.204--4.7970.004Age0.9940.962--1.0260.307BMI\> 300.8580.389--1.8940.495ASAIII--IV1.3460.635--2.8540.156CCI\> 51.7200.759--3.8980.025Diabetes mellitusYes1.2970.478--3.5220.155Ischemic heart diseaseYes0.9330.250--3.4870.303Cerebrovascular diseaseYes1.0900.185--6.4320.644Surgery typePalliative0.6060.059--6.2730.980Neoadjuvant treatmentYes1.4300.645--3.1700.260Anastomosis typeStapled1.3100.125--13.7270.809Ligation of IMAHigh2.3450.939--5.8560.167Air-water testNo1.3390.529--3.3920.350IleostomyNo0.8840.405--1.9300.749Simultaneous operationYes1.1880.436--3.2370.450T stageT3--42.2501.052--4.8150.017Approach of surgeryOpen0.6330.316--1.2690.186Anastomosis level from anal verge\< 53.2860.933--11.5690.064Anastomosis level from anal verge5--122.6290.636--10.8680.182*BMI* body mass index, *ASA* American Society of Anesthesiologists classification score, *CCI* Charlson comorbidity index score, *IMA* inferior mesenteric artery, *AL* anastomotic leakage

AL and 30- and 90-day mortality {#Sec12}
-------------------------------

The 30-day mortality rate was higher in patients with AL in the sigmoid (15.4% vs 0%, *p* = 0.002) and rectal (5.8% vs 1%, *p* = 0.016) surgery sub-groups. Similarly, 90-day mortality rate remained higher in leaking patients (sigmoid 15.4% vs 1.6%, *p* = 0.032; rectal 8.7% vs 2.1%, *p* = 0.008).

AL and long-term outcomes {#Sec13}
-------------------------

The median time of follow-up was 38 (Q1 22; Q3 53) months. The AL after sigmoid surgery impaired OS and DFS (Fig. [2](#Fig2){ref-type="fig"}a, b). Similarly, the AL impaired OS and DFS (Fig. [2](#Fig2){ref-type="fig"}c, d) after rectal surgery. Fig. 2Overall and disease-free survival in sigmoid and rectal surgery

Further, AL was adjusted for the stage of the disease, gender, age, and comorbidities (CCI score) by COX regression analysis in the study cohort. After, the AL remained a significant factor for impaired OS (HR (95% CI) 1.53 (1.01--2.32), *p* = 0.041) and DFS (HR (95% CI) 1.51 (1.05--2.19), *p* = 0.026) (Table [5](#Tab5){ref-type="table"}). Table 5Cox regression (multivariable) analysis for overall and disease-free survival in the study cohortOverall survivalDisease-free survivalHR (95% CI)*p*HR (95% CI)*p*Anastomotic leakageNo1 (reference)1 (reference)Yes1.53 (1.01--2.32)0.0411.51 (1.05--2.19)0.026Stage of diseaseI1 (reference)1 (reference)II1.26 (0.72--2.20)0.4031.52 (0.93--2.48)0.090III2.28 (1.38--3.78)0.0012.94 (1.88--4.59)0.001IV5.87 (3.26--10.56)0.0016.04 (3.51--10.38)0.001GenderMale1 (reference)1 (reference)Female1.03 (0.76--1.39)0.8320.95 (0.73--1.23)0.714Age (years)≤ 551 (reference)1 (reference)56--701.15 (0.71--1.85)0.5661.02 (0.70--1.49)0.889≥ 711.90 (1.16--3.11)0.0101.15 (0.76-1.73)0.498Comorbidities by CCI0--51 (reference)1 (reference)≥ 62.48 (1.64--3.74)0.0012.14 (1.48--3.10)0.001*CCI* Charlson comorbidity index score

Discussion {#Sec14}
==========

Our study demonstrated that AL impairs long-term outcomes of the patients undergoing surgery for sigmoid and rectal cancer. Severe comorbidities, male sex, and advanced tumor stage are the risk factors for AL.

Several recent studies investigated the risk factors for AL because the identification of high-risk patients and avoidance of anastomosis in these patients could improve treatment outcomes \[[@CR8]--[@CR12]\]. Previously, studies demonstrated male gender as a risk factor for AL after rectal surgery, and our results were consistent with these findings \[[@CR3], [@CR8], [@CR9], [@CR13], [@CR14]\]. Male gender is thought to increase the AL rate because of more technically demanding surgery in the narrow and deeper pelvis of men \[[@CR13]\]. There is a possibility that hormonal functions may impact anastomotic healing as well \[[@CR15], [@CR16]\]. The advanced stage of tumor also makes surgery more technically challenging, and it was confirmed as another risk factor for AL by our study. Interestingly, we did not find a higher AL rate in patients receiving low anastomosis. These findings are conflicting with some previous reports indicating a higher risk for low anastomoses \[[@CR3], [@CR17]\]. Although, in our results, there was a strong tendency for higher AL rate in low anastomoses (≤ 5 cm (10.9%) vs 6--12 cm (13.6%) vs \> 12 cm (5.8 %), *p* = 0.137), and it might be that our study was underpowered to detect significant differences because of the relatively small sample size.

Lower anastomoses may be secured by diverting ileostomy. However, the evidence on the impact of ileostomy on preventing the leak or reducing the symptoms is conflicting. Two meta-analyses concluded that stoma reduces the rate of AL following low anterior resection \[[@CR12], [@CR18]\]. In contrast, our study did not confirm that ileostomy prevents AL. This finding is consistent with some previous studies \[[@CR19], [@CR20]\]. A temporary ileostomy may not prevent the AL but rather diminish its symptoms and consequences. Further, the true rate of AL in patients receiving ileostomy may be underestimated because usually asymptomatic patients do not undergo testing for anastomosis integrity at the early postoperative period \[[@CR21], [@CR22]\]. Similarly, in our study, asymptomatic patients underwent anastomosis integrity testing just before the ileostomy closure; thus, some cases of AL in patients who receive ileostomy might have been underestimated as well. Therefore, further studies are required to clarify the role of ileostomy in the prevention of the AL.

The existing data on AL impact on the long-term outcomes are conflicting as well. A recent study from the Mayo Clinic revealed similar OS, DFS, and local recurrence rates between patients with or without AL \[[@CR6]\]. Propensity score-matched analysis by Sueda et al. also demonstrated a similar OS rate in AL and non-AL patients, except the higher rate of local recurrence in case of leakage \[[@CR23]\]. In contrast, the previous meta-analysis by Bashir et al. concluded that patients with AL have a lower 5-year OS of 58% compared with 73% in non-leaking patients \[[@CR24]\]. Moreover, the negative impact of AL on OS was indicated by Yang et al. and a large Scandinavian cohort study by Stormark et al. \[[@CR25], [@CR26]\]. Our study confirmed the impaired OS and DFS in patients suffering from AL, and there is a rationale for such findings. First, AL may lead to an increased rate of local recurrence because of cancer cell implantation and progression at the inflamed leaking anastomotic site \[[@CR27], [@CR28]\]. Despite AL occurs after surgical tumor removal, several viable tumor cells remain intraluminally, proximally, and distally to cancer sites \[[@CR29]\]. These cells were identified after the rectal wash-out or were washed-out from histologically tumor-free stapled doughnuts \[[@CR30], [@CR31]\]. The pre-clinical model confirms these intraluminal cancer cells can implant at the anastomotic site and initiate tumor growth in experimental animals \[[@CR32]\]. Additionally, the leakage results in a local inflammation, which may further contribute to the increased risk of tumor cell implantation and proliferation at the anastomotic site \[[@CR33]\]. Moreover, the AL is associated with an increased systemic inflammatory response as shown by increased levels of CRP, and such condition may be related to the development and progression of the malignancy \[[@CR34], [@CR35]\]. AL is also associated with the delay or omission of the adjuvant chemotherapy. Therefore, AL may have a negative impact on long-term outcomes, especially in patients with the advanced stage of the disease, where adjuvant chemotherapy is necessary \[[@CR36]--[@CR39]\].

The present study has some limitations, including the retrospective design of the study. However, a considerable sample size, multicenter approach, and significant national registry-based long-term follow-ups increase the power of the study to demonstrate that AL is associated with impaired long-term outcomes in patients undergoing surgery for left-sided CRC. Future research is needed to find strategies to reduce or prevent the rate of AL in such patients \[[@CR40]\].

Conclusion {#Sec15}
==========

ASA score of III--IV is an independent risk factor for AL after sigmoid surgery, and male sex, higher CCI score, and advanced tumor stage are among risk factors for AL after rectal surgery. AL impairs the long-term survival in patients undergoing left-sided colorectal surgery.
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